Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Progressive Supranuclear Palsy Clinical Trial Platform
NCT07173803Phase 2Recruiting
- Start
- Jul 2026
- Primary completion
- Sep 2030
- Modality
- Peptides, Small Molecules, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in progressive supranuclear palsy (PSP) comparing Regimen A: AADvac1 vs Placebo with Regimen B: LM11A-31 vs Placebo (2 arms). Primary endpoint: Disease progression at 52 weeks. Started Jul 2026; status: recruiting.
02
Drugs
AADvac1LM11A-31
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT07173803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07173803.